Medical Hypotheses
Volume 58, Issue 1 , Pages 18-23 , January 2002

Activation and release of degradative proteinases within the myocardium are the trigger for ventricular remodeling in chronic heart failure

Received 14 September 2000 ,Accepted 29 May 2001.

References 

  1. Goldstein S, Ali AS, Sabbah H. Ventricular remodeling. Mechanisms and prevention. Cardiol Clin. 1998;16:623–632
  2. Rumberger JA, Behrenbeck T, Breen JR, Reed JE, Gersh BJ. Nonparallel changes in global left ventricular chamber volume and muscle mass during the first year after transmural myocardial infarction in humans. J Am Coll Cardiol. 1993;21:673–682
  3. Kostuk WJ, Kazamias TM, Gander MP, Simon AL, Ross J. Left ventricular size after acute myocardial infarction. Serial changes and their prognostic significance. Circulation. 1973;47:1174–1179
  4. Lee TH, Hamilton MA, Stevenson LW. Impact of left ventricular cavity size on survival in advanced heart failure. Am J Cardiol. 1993;72:672–676
  5. Francis G, Dohn J, Johnson G, Rector T, Goldman S, Simon A. Plasma norepinephrine, plasma renin activity, and congestive heart failure. Relations to survival and effects of therapy inV-HeFT-II. Circulation. 1993;87:IV40–IV48
  6. N Engl J Med. 1987;316:1429–1435
  7. N Engl J Med. 1991;325:293–302
  8. Pfeffer M, Braunwald E, Moye L. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial. N Engl J Med. 1992;327:669–677
  9. Packer M, Bristow MR, Cohn JN. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996;334:1349–1355
  10. Lancet. 1999;353:2001–2007
  11. Lancet. 1999;353:9–13
  12. Bristow MR, Ginsburg R, Minobe W. Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. N Engl J Med. 1982;307:205–211
  13. Zile MR, Koide M, Sato H. Role of microtubules in the contractile dysfunction of hypertrophied myocardium. J Am Coll Cardiol. 1999;33:250–260
  14. Tyagi SC. Proteinases and myocardial extracellular matrix turnover. Mol Cell Biochem. 1997;168:1–12
  15. Li , Feldman , Tiernan . Differential expression of tissue inhibitors of metalloproteinases in the failing human heart. Circulation. 1998;98:1728–1734
  16. Mann DL, Kent RL, Parsons B, Cooper Gt. Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation. 1992;85:790–804
  17. Yamada T, Horiuchi M, Dzau VJ. Angiotensin II type 2 receptor mediates programmed cell death. Proc Natl Acad Sci USA. 1996;93:156–160
  18. Cheng W, Li B, Kajstura J. Stretch-induced programmed myocyte cell death. J Clin Invest. 1995;96:2247–2259
  19. Teiger E, Than VD, Richard L. Apoptosis in pressure overload-induced heart hypertrophy in the rat. J Clin Invest. 1996;97:2891–2897
  20. Bialik S, Geenen DL, Sasson IE. Myocyte apoptosis during acute myocardial infarction in the mouse localizes to hypoxic regions but occurs independently of p53. J Clin Invest. 1997;100:1363–1372
  21. Maulik N, Yoshida T, Das DK. Oxidative stress developed during the reperfusion of ischemic myocardium induces apoptosis. Free Radic Biol Med. 1998;24:869–875
  22. Pulkki KJ. Cytokines and cardiomyocyte death. Ann Med. 1997;29:339–343
  23. Schmidt U, Hajjar RJ, Gwathmey JK. The force-interval relationship in human myocardium. J Card Fail. 1995;1:311–321
  24. Lowes BD, Minobe W, Abraham WT. Changes in gene expression in the intact human heart. Downregulation of alpha-myosin heavy chain in hypertrophied, failing ventricular myocardium. J Clin Invest. 1997;100:2315–2324
  25. Packer M, Carver JR, Rodeheffer RJ. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med. 1991;325:1468–1475
  26. Cohn JN, Goldstein SO, Greenberg BH. Adose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators. N Engl J Med. 1998;339:1810–1816
  27. Gerdes A, Kellerman S, Moore J. Structural remodeling of cardiac myocytes in patients with ischemic cardiomyopathy. Circulation. 1992;86:426–430
  28. Cleutjens JP. Regulation of collagen degradation in the rat myocardium after infarction. J Mol Cell Cardiol. 1995;27:281–292
  29. Bishop J, Rhodes S, Laurent G, Low R, Stirewalt W. Increased collagen synthesis and decreased collagen degradation in right ventricular hypertrophy induced by pressure overload. Cardiovasc Rese. 1994;28:1581–1585
  30. Olivetti G, Capasso JM, Sonnenblick EH, Anversa P. Side-to-side slippage of myocytes participates in ventricular wall remodeling acutely after myocardial infarction in rats. Circ Res. 1990;67:23–34
  31. Zafeiridis A, Jeevanandam V, Houser SR, Margulies KB. Regression of cellular hypertrophy after left ventricular assist device support. Circulation. 1998;98:656–662
  32. Weber KT, Janicki JS, Shroff SG, Pick R, Chen RM, Bashey RI. Collagen remodeling of the pressure-overloaded, hypertrophied nonhuman primate myocardium. Circ Res. 1988;62:757–765
  33. Boluyt M, O'Neill L, AL M. Alterations in cardiac gene expression during the transition from stable hypertrophy to heart failure: marked upregulation of genes encoding extracellular matrix components. Circ Res. 1994;75:23–32
  34. Takahashi N, Calderone A, Izzo NJ, Maki TM, Marsh JD, Colucci WS. Hypertrophic stimuli induce transforming growth factor-beta 1 expression in rat ventricular myocytes. J Clin Invest. 1994;94:1470–1476
  35. Tyagi SC, Lewis K, Pikes D. Stretch-induced membrane type matrix mloproteinase and tissue plasminogen activator in cardiac fibroblast cells. J Cell Physiol. 1998;176:374–382
  36. Zhao M, Zhang H, Robinson T, Factor S, Sonnenblick E, Eng C. Profound structural alterations of the extracelluar collagen matrix in postischemic dysfunctional (‘stunned’) but viable myocardium. J Am Coll Cardiol. 1987;10:1322–1334
  37. Baghelai K, Marktanner R, Dattilo JB. Decreased expression of tissue inhibitor of mloproteinase 1 in stunned myocardium. J Surg Res. 1998;77:35–39
  38. Pieterma A, de Jong N, Sluiter W, Koster JF. Studies on the interaction os leucocytes and the myocardial vasculature. I. Effect of hypoxia on the adherence of blood granulocytes. Mol Cell Biochem. 1992;116:197–202
  39. Simms H, D'Amico R. Regulation of polymorphonuclear leukocyte cytokine receptor expression: the role of altered oxygen tensions and matrix proteins. J Immunol. 1996;157:3605–3616
  40. Derevianko A, D'Amico R, Simms H. Polymorphonuclear leucocyte (PMN)-derived inflammatory cytokines—regulation by oxygen tension and extracellular matrix. Clin Exp Immunol. 1996;106:560–567
  41. Frangogiannis NG, Lindsey ML, Michael LH. Resident cardiac mast cells degranulate and release preformed TNF- alpha, initiating the cytokine cascade in experimental canine myocardial ischemia/reperfusion. Circulation. 1998;98:699–710
  42. Kanwar S, Kubes P. Ischemia/reperfusion-induced granulocyte influx is a multistep process mediated by mast cells. Microcirculation. 1994;1:175–182
  43. Matsuda H, Kawakita K, Kiso Y, Nakano T, Kitamura Y. Substance P induces granulocyte infiltration through degranulation of mast cells. J Immunol. 1989;142:927–931
  44. Iizuka K, Kawaguchi H, Yasuda H, Kitabatake A. The role of calcium activated neutral protease on myocardial cell injury in hypoxia. Jpn Heart J. 1992;33:707–715
  45. Tijsen MJ, Peters SM, Bindels RJ, van O, Wetzels JF. Glycine protection against hypoxic injury in isolated rat proximal tubules: the role of proteases. Nephrol Dial Transplant. 1997;12:2549–2556
  46. Charney R, Takahashi S, Zhao M, Sonnenblick E, Eng C. Collagen loss in the stunned myocardium. Circulation. 1992;85:1483–1490
  47. Nicoletti A, Heudes D, Mandet C, Hinglais N, Bariety J, Michel JB. Inflammatory cells and myocardial fibrosis: spatial and temporal distribution in renovascular hypertensive rats. Cardiovasc Res. 1996;32:1096–1107
  48. Kukielka GL, Smith CW, Manning AM, Youker KA, Michael LH, Entman ML. Induction of interleukin-6 synthesis in the myocardium. Potential role in postreperfusion inflammatory injury. Circulation. 1995;92:1866–1875
  49. Meldrum DR, Cleveland JCJ, Cain BS, Meng X, Harken AH. Increased myocardial tumor necrosis factor-alpha in a crystalloid- perfused model of cardiac ischemia-reperfusion injury. Ann Thorac Surg. 1998;65:439–443
  50. Gwechenberger M, Mendoza LH, Youker KA. Cardiac myocytes produce interleukin-6 in culture and in viable border zone of reperfused infarctions. Circulation. 1999;99:546–551
  51. Marx N, Neumann FJ, Ott I. Induction of cytokine expression in leukocytes in acute myocardial infarction. J Am Coll Cardiol. 1997;30:165–170
  52. Li YY, McTiernan CF, Feldman AM. , Proinflammatory cytokines regulate tissue inhibitors of mloproteinases and disintegrin mloproteinase in cardiac cells. Cardiovasc Res. 1999;42:162–172
  53. Katwa LC, Campbel SE, Tyagi SC, Lee SJ, Cicila GT, Weber KT. Cultured myofibroblasts generate angiotensin peptides de novo. J Mol Cell Cordiol. 1997;29:1375–1386
  54. Harada M, Itoh H, Nakagawa O. Significance of ventricular myocytes and nonmyocytes interaction during cardiocyte hypertrophy: evidence for endothelin-1 as a paracrine hypertrophin factor from cardiac nonmyocytes. Circulation. 1997;96:3737–3744
  55. Chapleau MW, Hajduczok G, Abbound FM. Suppression of baroreceptor discharge by endothelin at high carotid sinus pressure. Am J Physiol. 1992;263:R103–R108
  56. Birks EJ, Yacoub MH. The role of nitric oxide and cytokines in heart failure. Coron Artery Dis. 1997;8:389–402
  57. Yue P, Massie BM, Simpson PC, Long CS. Cytokine expression increases in nonmyocytes from rats with postinfarction heart failure. Am J Physiol. 1998;275:H250–H258
  58. Bozkurt B, Kribbs SB, Clubb FJ. Jr. Pathophysiologically relevant concentrations of tumor necrosis factor- alpha promote progressive left ventricular dysfunction and remodeling in rats. Circulation. 1998;97:1382–1391
  59. Rohde LE, Ducharme A, Arroyo LH. Matrix mloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation. 1999;99:3063–3070
  60. Peterson T, Sanchez B, Robertson A. Matrix mloproteinase inhibitor PD 166793 alters progression of heart failure in the myocardial infarcted rat. Circulation. 1998;98:2200A
  61. McElmurray JH, Mukherjee R, New RB. Angiotensin-converting enzyme and matrix mloproteinase inhibition with developing heart failure: comparative effects on left ventricular function and geometry. J Pharmacol Exp Ther. 1999;291:799–811
  62. Spinale FG, Coker ML, Krombach SR. Matrix mloproteinase inhibition during the development of congestive heart failure: effects on left ventricular dimensions and function. Circ Res. 1999;85:364–376
  63. Peterson J, Rosebury W, Robertson A. Matrix mloproteinase inhibition blocks progression of heart failure. Circulation. 1997;96:I–520
  64. Murohara T, Guo JP, Lefer AM. Cardioprotection by a novel recombinant serine protease inhibitor in myocardial ischemia and reperfusion injury. J Pharmacol Exp Ther. 1995;274:1246–1253
  65. Lee JK, Zaidi SH, Liu P. A serine elastase inhibitor reduces inflammation and fibrosis and preserves cardiac function after experimentally-induced murine myocarditis. Nat Med. 1998;4:1383–1391
  66. Shimai S, Takano T, Seino Y, Tanaka K, Hayakawa H. Role of PMN elastase on ischemic myocardial injury in evolving myocardial infarction: correlation with clinical parameters and intervention by protease inhibitor ulinastatin. Jpn Circ J. 1989;53:1144–1151
  67. Farrell D, Wei C-C, Bradley W. Inhibition of angiotensin II formation in the dog heart in vivo by a novel serine protease inhibitor BCX-1470. Circulation. 1998;98:I–719

PII: S0306-9877(01)91420-3

doi: 10.1054/mehy.2001.1420

Medical Hypotheses
Volume 58, Issue 1 , Pages 18-23 , January 2002

Article Tools